SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-060579
Filing Date
2024-05-15
Accepted
2024-05-15 17:04:56
Documents
62
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ikt-20240331.htm   iXBRL 10-Q 1099266
2 EX-31.1 ikt-ex31_1.htm EX-31.1 13756
3 EX-31.2 ikt-ex31_2.htm EX-31.2 13819
4 EX-32.1 ikt-ex32_1.htm EX-32.1 9948
5 EX-32.2 ikt-ex32_2.htm EX-32.2 9946
  Complete submission text file 0000950170-24-060579.txt   4998112

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ikt-20240331.xsd EX-101.SCH 870956
66 EXTRACTED XBRL INSTANCE DOCUMENT ikt-20240331_htm.xml XML 696486
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

IRS No.: 263407249 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39676 | Film No.: 24952392
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)